From left, Darren Benedick and Mark Slatcoff set up the 80-L bioreactor for rhIL-15 production.

Cancer immunotherapy is a type of treatment in which the body’s own immune system is used to attack and kill cancer cells or keep them from spreading. To date, the immunotherapy agent interleukin-2 (IL-2) has been approved by the U.S. Food and Drug Administration for treating certain types of melanoma and kidney cancer.1